Founded by Brent Vaughan, Cognito Therapeutics, Inc. is a medical equipment manufacturing startup on a mission to improve the lives of patients living with neurodegenerative diseases. With an impressive $73M raised in Series B funding from FoundersX Ventures, IAG Capital Partners, and Alzheimer's Drug Discovery Foundation, they are well on their way to revolutionizing the field of neuromodulation. Their investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease. 

By using sensory stimulation to evoke gamma oscillations in the brain, Cognito has found a way to improve synaptic connections between neurons, activate microglia, and enhance removal of pathological proteins from the brain. This leads to reduced neurodegeneration and brain atrophy, as well as improved sleep, cognitive and functional abilities. With a self-administered use that can be performed in the comfort of patients’ homes, Cognito's personalized sensory stimulation facilitates long-term engagement, unlocking the potential of each patient. Get ready to experience the future of neuromodulation with Cognito Therapeutics.